Apogee Therapeutics

APGENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$10.166 B

$134.84 +0.26%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$255.8M

Loss-making

Shares outstanding

74,882,396

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#10Halozyme TherapeuticsHALO$12.2B
#11Bio-TechneTECH$11.3B
#12Apogee TherapeuticsAPGE$10.2B
#13Krystal BiotechKRYS$9.66B
#14RepligenRGEN$9.25B

Where these numbers come from

Share counts and financials for Apogee Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.